ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Venatorx Pharmaceuticals to Present Data at IDWeek 2021

September 27, 2021 GMT

MALVERN, Pa.--(BUSINESS WIRE)--Sep 27, 2021--

Venatorx Pharmaceuticals today announced that the Company, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.

Session A1. Novel Antimicrobial Agents

  • Oral Presentation #133ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam.A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.
  • Poster Presentation #1055ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236. A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.
  • Poster Presentation #1063ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam.A.R. Mack, C. Bethel, S. Marshall, R. Patel, D. van Duin, V.G. Fowler, D.D. Rhoads, M. Jacobs, F. van den Akker, D.A. Six, G. Moeck, K.M. Papp-Wallace, R.A. Bonomo.

ADVERTISEMENT

Session A3. Resistance Mechanisms

  • Poster Presentation #1286Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC). A.R. Mack, C. Bethel, M.A. Taracilla, F. van den Akker, B.A. Miller, T. Uehara, D.A. Six, K.M. Papp-Wallace, R.A. Bonomo.

Session A4. Treatment of antimicrobial resistant infections

  • Oral Presentation #203Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection.M. Hackel, M.G. Wise, D.F. Sahm.
  • Poster Presentation #1253Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance. M. Hackel, M.G. Wise, D.F. Sahm.
  • Poster Presentation #1293In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020. M. Hackel, M.G. Wise, D.F. Sahm.

Session D1. Diagnostics: Bacteriology/mycobacteriology

  • Poster Presentation #642Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation. V. Gupta, K. Yu, J.M. Pogue, C.J. Clancy.

ADVERTISEMENT

Session N10. Healthcare-Associated Infections: Gram-Negatives (MDR-GNR)

  • Poster Presentation #786Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) from 2016-2019: A multicenter evaluation. V. Gupta, K. Yu, J.M. Pogue, J. Weeks, C.J. Clancy.

About Venatorx Pharmaceuticals, Inc.

Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics. For more information about Venatorx, please visit www.venatorx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210927005630/en/

CONTACT: MEDIA CONTACT:

Heather Hunter

Vice President, Communications

hunter(at)venatorx(dot)com

484.329.8327

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Venatorx Pharmaceuticals, Inc.

Copyright Business Wire 2021.

PUB: 09/27/2021 12:00 PM/DISC: 09/27/2021 12:02 PM

http://www.businesswire.com/news/home/20210927005630/en